Navigation Links
Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic,Control in Subjects with Type 2 Diabetes Compared to Metformin,Alone

liptin

Saxagliptin is an investigational drug under development by Bristol-Myers Squibb and AstraZeneca. It is being studied as a once daily antidiabetic in the class of dipeptidyl peptidase-4 (DPP-4) inhibitors for the treatment of Type 2 diabetes. DPP-4 inhibitors are a class of compounds that work by affecting the action of natural hormones in the body called incretins. Incretins decrease blood sugar by increasing consumption of sugar by the body, mainly through increasing insulin production in the pancreas, and by reducing production of sugar by the liver.

Bristol-Myers Squibb and AstraZeneca Partnership

In January 2007, Bristol-Myers Squibb and AstraZeneca entered into a collaboration to develop and commercialize saxagliptin and dapagliflozin, two compounds under investigation by Bristol-Myers Squibb for the treatment of diabetes. Both companies will jointly set development and commercial strategy for the two compounds. AstraZeneca will provide funding for the majority of currently planned development activities; additional development activity will be funded equally.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global pharmaceutical and related healthcare products company whose mission is to extend and enhance human life.

Bristol-Myers Squibb Forward-Looking Statement

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the development and commercialization of products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that the development of the products described in this release will be successful, tha
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
2. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
3. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
4. Study Demonstrated Rozerem (ramelteon) Does Not Affect Middle-of-the-Night Balance in Older Adults with Insomnia
5. Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care
6. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
7. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine
8. Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks
9. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
10. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
11. 12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA (methylphenidate transdermal system)
Post Your Comments:
(Date:11/26/2008)...swire/ -- Children whose eyes are misaligned and p...f developing mental illness by early adulthood, ac...hed this month in Pediatrics , the official journa... The retrospective study examined the medical rec...yes) and compared them with records of children ma...
(Date:11/25/2008)... , Audio and Web Video Resources to accompany ...log. Please see the bottom of this release for det...RNewswire-USNewswire/ -- A Mayo Clinic study shows... having a stroke -- and as a result -- delay seeki...ndings appear in the current issue of Emergency Me...
(Date:11/25/2008)...swire/ -- Proteolix, Inc., a,leader in the discov...get,protein degradation pathways in cancer and au... two ongoing Phase 2 clinical trials of carfilzomi...coming 50th Annual Meeting of the,American Societ...n a new class,of specific proteasome inhibitors a...
(Date:11/25/2008)...Assess Survival of Patients Receiving Litx versus ...cellular Carcinoma , , BELLEVUE, Wash., Nov... (LSO) today announced the completion of enrollmen...sion Therapy(TM) (Litx(TM)) as a treatment for unr...wn as hepatoma or primary liver cancer. , , ...
Breaking Medicine Technology:Eye Divergence in Children Triples Risk of Mental Illness 2Do You Know You're Having a Stroke? 2Do You Know You're Having a Stroke? 3Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Iomai CEO to Speak at BIO CEO 26 Investor Forum on Feb 12 3065 1Iomai CEO to Speak at BIO CEO 26 Investor Forum on Feb 12 3065 2Tourtellotte Solutions Fusion DMC 28TM 29 Unifies the World of Bio Pharma Documents 11110 1Tourtellotte Solutions Fusion DMC 28TM 29 Unifies the World of Bio Pharma Documents 11110 2Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies 3064 1Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies 3064 2Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies 3064 3Tutogen Medical Inc Reports First Quarter Fiscal 2008 Financial Results 3059 1Tutogen Medical Inc Reports First Quarter Fiscal 2008 Financial Results 3059 2Tutogen Medical Inc Reports First Quarter Fiscal 2008 Financial Results 3059 3Tutogen Medical Inc Reports First Quarter Fiscal 2008 Financial Results 3059 4Tutogen Medical Inc Reports First Quarter Fiscal 2008 Financial Results 3059 5Tutogen Medical Inc Reports First Quarter Fiscal 2008 Financial Results 3059 6Tutogen Medical Inc Reports First Quarter Fiscal 2008 Financial Results 3059 7Tutogen Medical Inc Reports First Quarter Fiscal 2008 Financial Results 3059 8
...--(BUSINESS WIRE)--Jun 6, 2007 - Inovio Biomedical...t of DNA vaccines,for cancers and infectious disea...calized cancers, announced today the company,deliv...esults and,new device innovations relating to its ...t the 10th Annual Meeting of the American,Society ...
...fficacy and Markers Demonstrated in Combination Tr...stCall/ --,EntreMed, Inc. , a clinical-stage pharm...y for the treatment of cancer and inflammatory,dis...from the Phase,1b study with Panzem(R) NCD (2ME2 o... (paclitaxel) in patients with metastatic,breast c...
Other Medicine Technology:Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with,Electroporation DNA Delivery Technology and New Devices at Gene,Therapy Meeting 2Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with,Electroporation DNA Delivery Technology and New Devices at Gene,Therapy Meeting 3Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with,Electroporation DNA Delivery Technology and New Devices at Gene,Therapy Meeting 4Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with,Electroporation DNA Delivery Technology and New Devices at Gene,Therapy Meeting 5Clinical Results From EntreMed's Panzem NCD and Taxol Breast Cancer,Study Presented at ASCO 2Clinical Results From EntreMed's Panzem NCD and Taxol Breast Cancer,Study Presented at ASCO 3Clinical Results From EntreMed's Panzem NCD and Taxol Breast Cancer,Study Presented at ASCO 4
(Date:12/2/2008).... 2 In response to the commentary ...ent Respiratory Infections, and the Vitamin D Defi...well known supplement experts, Nordic Naturals ann...no threat or compromise to consumers and actually ...low in natural Vitamin A. According to Karin Yien,...
(Date:12/2/2008)...re/ -- The Healthcare group at Frost & Sulliva... to announce that it will be,hosting an interacti...diology,Markets on 11 December 2008 at 3pm GMT. ,...h/20081117/FSLOGO ) , With most diagnostic ...ndors in Europe are faced with an immense challeng...
(Date:12/2/2008)...Dec. 2 Internationally recognized,...nvited speaker for this,year,s annual meeting of ... (Photo: http://www.newscom.com/cgi-bin/prnh/200... minimally invasive (or ,Goldilocks,) anesthesia,...K 101, minimally invasive,anesthesia for minimall...
(Date:12/2/2008)... World Wide Dictation Service, one of the premier...cription, and legal dictation transcription, has ..., a non-profit organization geared to the betterme...r families throughout Lower Westchester County, Ne...WEB) December 3, 2008 -- World Wide Dictation Serv...
Breaking Medicine News(10 mins):Health News:Nordic Naturals Offers Cod Liver Oil Solutions in Response to Recent Vitamin A and Vitamin D Controversy 2Health News:Will Diagnostic Cardiology Vendors Look to Product Innovation? 2Health News:World Wide Dictation Service Teams up with TMATT for Local Thanksgiving Community Dinner 2
...ity to develop 'much cheaper' drugs to combat HIV/...available first and second line treatment of the d...man in the country. Stating that the Indian compan...ging down the price of first and second line HIV d...
...om one evening in May, hoteliers, ambassadors, cel...ie gras, oysters and sushi while they talked about...skan king crab, French wine and melt-in-your-mouth...assembled crowd discussed ways of putting Bangkok ...
...t bread companies is not happy with the proposal t... acid. They are petitioning the state and federal/...e of such a proposal is to enhance the foliate lev... folic acid fortification will help offset birth d...
...er Surayud Chulanont, has defended his government'...ns of three patented// drugs-in spite of US worrie.... "We still defend what we have done, and we can ...ntries as well the world community," Surayud was q...
Other Medicine News:Health News:Bangkok Lures Visitors With Its Growing Gourmet Scene 2Health News:Thailand Unfazed As US Worries Over Copyright Violations 2
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
Medicine Products: